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Introduction
NOMID/CINCA is the most severe phenotype of cryo-
pyrin-associated periodic syndrome (CAPS), characterized
by persistence of inflammation-mediated symptoms and
overproduction of interleukin (IL)-1b, associated with sig-
nificant morbidity, if untreated. In CAPS-patients early
initiation of anti-IL1b-treatment appears to prevent severe
disease sequelae. However, canakinumab as a 1st-line
treatment in young infants suffering from NOMID has
been scarcely reported.
Objectives





A late-preterm (37-weeks- gestational-age) girl presented
fever, urticarial-like rash, perilimbal redness, meningitis,
elevation of WBC/neutrophils, ESR, CRP on 20 hours of
life and severe anemia necessitating RBC-transfusion in
the 5th day of life. NOMID/CINCA was suspected on the
basis of persistence of elevated inflammatory (including
SAA) markers in the absence of infection-causative organ-
isms in blood, CSF and urine, of non-responsiveness to
antibiotics, of persistent CNS inflammation (CSF pleiocy-
tosis and elevated protein) and of neutrophilic infiltration
(revealed by skin biopsy) in the areas of urticarial-like
rash. The detection of the c.1792A>T (p.Ile598Phe) muta-
tion (de-novo as it was no detected in parents) in exon
3 of the NLRP3-gene, causative for NOMID/CINCA
according to the infevers-database, confirmed the diagno-
sis. Brain-MRI was normal despite persistent CNS-
inflammation represented by pleiocytosis and elevated
protein and IL-6 and IL-8-levels in CSF (lumbar puncture
performed on the 1st-day and 3rd-month of life). In periph-
eral blood IL-1b, IL-6 and IL-8 were undetectable. Opthal-
moscopy/fundoscopy, and auditory-evoked-potentials
were normal. After providing immunizations anti-IL1b-
treatment with canakinumab 4mg/kg/8 weeks was initiated
in the age of 4-months. Fever and rash remitted in 24h.
Inflammatory markers normalized after 5-days. On
16-months of age the disease remains into remission. The
only sign that persists is perilimbal redness. Mental and
motor development is normal. No sensorineural or skeletal
manifestations developed. Self-limited, 24h-duration, scarce
urticarial-rash appeared in the age of 6 and 15 months
with concomitant mild elevation of WBC/ neutrophils and
SAA but normal CRP and ESR levels. Repeat MRI revealed
absence of CNS involvement and lumbar puncture was not
repeated. No adverse reactions presented apart from 1 URI
after 12-months of canakinumab treatment.
Conclusion
Early initiation of canakinumab-treatment in CINCA leads
to disease-remission and appears to prevent the develop-
ment severe disease-sequelae such as CNS, sensorineural
and skeletal manifestations. The patient presented no
severe adverse reactions.
Pediatric Rheumatology Unit, 1st Department of Pediatrics, University of
Athens, Children’s Hospital “Aghia Sofia”, Medical School, Athens, Greece
Tsinti et al. Pediatric Rheumatology 2015, 13(Suppl 1):P209
http://www.ped-rheum.com/content/13/S1/P209
© 2015 Tsinti et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Consent to publish
Written informated consent for publication of their clini-
cal details was obtained from the patient/parent/guardian/
relative of the patient.
Published: 28 September 2015
doi:10.1186/1546-0096-13-S1-P209
Cite this article as: Tsinti et al.: Safe and effective canakinumab-
treatment of neonatal onset multisystem inflammatory disease
(NOMID)/ chronic infantile neurologic cutaneous and articular (CINCA).
Pediatric Rheumatology 2015 13(Suppl 1):P209.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tsinti et al. Pediatric Rheumatology 2015, 13(Suppl 1):P209
http://www.ped-rheum.com/content/13/S1/P209
Page 2 of 2
